Mechanistically, YTHDC2 was shown to bind directly to the mRNA of m6A-modified solute carrier 7A11 (SLC7A11), promoting its decay and thereby inhibiting cysteine uptake, which blocks downstream antioxidant programs, contributing to its anti-tumor activity. The gene discussed is YTHDC2; the disease is neoplasm.